Hazard ratios from network meta-analysis

Hazard ratios for first line treatments relative to gefitinib estimated using a Bayesian multi-state network meta-analyis (NMA).

mstate_nma_hr

Format

A data.table with the following columns:

line

Line of treatment. Either first or second.

model

The statistical model.

tx_name

Name of the treatment.

month

Trial month.

transition

The health state transition.

mean

Mean hazard ratio from the posterior distribution.

median

Median hazard ratio from the posterior distribution.

l95

Lower limit of 95 percent credible interval from posterior distribution.

u95

Upper limit of the 95 percent credible interval from the posterior distribution.

See also

mstate_nma_surv, mstate_nma_hazard

Examples

head(mstate_nma_hr)
#>    line   model   tx_name month            transition      mean    median
#> 1:    1 Weibull erlotinib     0 Stable to progression 1.0000000 1.0000000
#> 2:    1 Weibull erlotinib     1 Stable to progression 0.7534282 0.6815825
#> 3:    1 Weibull erlotinib     2 Stable to progression 0.6267102 0.5969727
#> 4:    1 Weibull erlotinib     3 Stable to progression 0.5727375 0.5528516
#> 5:    1 Weibull erlotinib     4 Stable to progression 0.5415394 0.5266664
#> 6:    1 Weibull erlotinib     5 Stable to progression 0.5208545 0.5028066
#>          l95       u95
#> 1: 1.0000000 1.0000000
#> 2: 0.2802687 1.5939442
#> 3: 0.3149345 1.0758052
#> 4: 0.3227722 0.9344328
#> 5: 0.2962844 0.8701981
#> 6: 0.2721158 0.8613339